As of 30 Sep 2025, 27 institutional investors reported holding $603,281,000 in principal (par value) of IONIS PHARMACEUTICALS INC - NOTE 4/0.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $3,000 | $4,111 | +$4,111 | 137.03% | 1 |
| 2025 Q3 | $603,281,000 | $742,167,044 | +$66,516,809 | 122.7% | 27 |
| 2025 Q2 | $549,711,910 | $555,202,909 | +$4,434,347 | 100.77% | 33 |
| 2025 Q1 | $546,181,909 | $539,251,665 | -$12,257,592 | 98.43% | 34 |
| 2024 Q4 | $561,167,910 | $543,386,109 | +$17,580,583 | 96.68% | 47 |
| 2024 Q3 | $542,279,000 | $542,911,225 | -$45,379,695 | 99.73% | 56 |
| 2024 Q2 | $589,177,000 | $608,248,104 | +$385,167 | 102.99% | 55 |
| 2024 Q1 | $590,897,000 | $584,045,653 | +$1,082,227 | 98.69% | 58 |
| 2023 Q4 | $585,686,397 | $618,187,865 | +$11,483,733 | 105.49% | 53 |
| 2023 Q3 | $567,259,143 | $556,222,929 | -$25,001,583 | 97.88% | 52 |
| 2023 Q2 | $581,292,500 | $550,280,148 | +$51,108,656 | 94.7% | 49 |
| 2023 Q1 | $537,145,000 | $490,429,590 | -$12,588,564 | 91.18% | 43 |
| 2022 Q4 | $557,303,500 | $517,088,656 | +$3,664,278 | 92.79% | 43 |
| 2022 Q3 | $485,742,000 | $484,656,098 | -$20,915,463 | 99.38% | 40 |
| 2022 Q2 | $505,668,900 | $464,773,416 | +$464,773,417 | 91.26% | 34 |